ESPERION THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Events

On January 31, 2020, Esperion Therapeutics, Inc. (the "Company") issued a press release announcing that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the Marketing Authorisation Application for the bempedoic acid tablet for the treatment of hypercholesterolemia and mixed dyslipidemia. A copy of the Press Release is furnished herewith as Exhibit 99.1.

On January 31, 2020, the Company issued a press release announcing that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the Marketing Authorisation Application for the bempedoic acid / ezetimibe fixed dose combination tablet for the treatment of hypercholesterolemia and mixed dyslipidemia. A copy of the Press Release is furnished herewith as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit No.                                 Description

  99.1          Press Release dated January 31, 2020.
  99.2          Press Release dated January 31, 2020.

    104       The cover page from this Current Report on Form 8-K, formatted in Inline
              XBRL.




                                       2

© Edgar Online, source Glimpses